Research and Markets has announced the addition of the "Open-Angle Glaucoma - Pipeline Review, H2 2016" report to their offering.
Open-Angle Glaucoma pipeline therapeutics constitutes close to 38 molecules. Out of which approximately 36 molecules are developed by Companies and remaining by the Universities/Institutes.
Open-Angle Glaucoma - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Open-Angle Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Open-Angle Glaucoma Open-angle glaucoma also called wide-angle glaucoma, this is the most common type of glaucoma. The structures of the eye appear normal, but fluid in the eye does not flow properly through the drain of the eye, called the trabecular meshwork. Signs and symptoms include gradual loss of peripheral vision, usually in both eyes and tunnel vision in the advanced stages. Risk factors include age, family history of glaucoma, long-term corticosteroid use and elevated internal eye pressure (intraocular pressure).
The molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 9, 17, 4 and 3 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.
Furthermore, this report also reviews of key players involved in therapeutic development for Open-Angle Glaucoma and features dormant and discontinued projects.
Key Topics Covered:
For more information about this report visit http://www.researchandmarkets.com/research/phd36j/openangle
View source version on businesswire.com: http://www.businesswire.com/news/home/20161010006046/en/Business Wire
Last updated on: 10/10/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.